{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:07:39Z","timestamp":1792681659846,"version":"4.5.0"},"reference-count":93,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eprac.2025.07.011","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:52:00Z","timestamp":1752681120000},"page":"1478-1487","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Hypoparathyroidism\u2014Current and Emerging Therapies"],"prefix":"10.1016","volume":"31","author":[{"given":"Sarah","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eprac.2025.07.011_bib1","doi-asserted-by":"crossref","first-page":"P1","DOI":"10.1530\/EJE-18-0609","article-title":"Standards of care for hypoparathyroidism in adults: a Canadian and International consensus","volume":"180","author":"Khan","year":"2019","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib2","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.1002\/jbmr.4675","article-title":"Epidemiology and financial burden of adult chronic hypoparathyroidism","volume":"37","author":"Bjornsdottir","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib3","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41574-024-01075-8","article-title":"Hypoparathyroidism: diagnosis, management and emerging therapies","volume":"21","author":"Khan","year":"2025","journal-title":"Nat Rev Endocrinol"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.011_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/jcm10030543","article-title":"Etiology and diagnosis of permanent hypoparathyroidism after total thyroidectomy","volume":"10","author":"Sitges-Serra","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib5","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1210\/clinem\/dgaa113","article-title":"Hypoparathyroidism","volume":"105","author":"Bilezikian","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib6","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1002\/jbmr.4714","article-title":"Etiology and pathophysiology of hypoparathyroidism: a narrative review","volume":"37","author":"Pasieka","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib7","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s12020-021-02629-w","article-title":"Canadian National hypoparathyroidism registry: an overview of hypoparathyroidism in Canada","volume":"72","author":"Khan","year":"2021","journal-title":"Endocrine"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib8","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1002\/jbmr.4691","article-title":"Evaluation and management of hypoparathyroidism summary statement and guidelines from the second international workshop","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.011_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.ecl.2018.07.009","article-title":"Hypoparathyroidism and the kidney","volume":"47","author":"Peacock","year":"2018","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"18","key":"10.1016\/j.eprac.2025.07.011_bib10","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1056\/NEJMcp1800213","article-title":"Hypoparathyroidism","volume":"380","author":"Gafni","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.eprac.2025.07.011_bib11","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1159\/000491042","article-title":"Hypoparathyroidism","volume":"51","author":"Hakami","year":"2019","journal-title":"Parathyroid Disord"},{"key":"10.1016\/j.eprac.2025.07.011_bib12","article-title":"Hypoparathyroidism","volume":"3","author":"Mannstadt","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.eprac.2025.07.011_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1244647","article-title":"Renal complications in chronic hypoparathyroidism \u2013 a systematic cross-sectional assessment. Original Research","volume":"14","author":"Gronemeyer","year":"2023","journal-title":"Front Endocrinol"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib14","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/jbmr.4673","article-title":"Complications, symptoms, presurgical predictors in patients with chronic hypoparathyroidism: a systematic review","volume":"37","author":"Yao","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib15","doi-asserted-by":"crossref","first-page":"e1466","DOI":"10.1210\/clinem\/dgae534","article-title":"Increased risk of chronic kidney disease after total thyroidectomy: a nationwide matched cohort study","volume":"110","author":"Reinke","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.011_bib16","doi-asserted-by":"crossref","DOI":"10.1007\/s12020-025-04187-x","article-title":"Impaired renal function in patients with permanent hypoparathyroidism after thyroidectomy: analysis of a nationwide cohort in Spain","author":"D\u00edez","year":"2025","journal-title":"Endocrine"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.011_bib17","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.surg.2024.05.005","article-title":"Long-term kidney outcomes in patients with permanent hypoparathyroidism after total thyroidectomy for benign disease: a population-based study","volume":"176","author":"Luk","year":"2024","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib18","first-page":"1617","article-title":"Bone mineral density in patients with chronic hypoparathyroidism","volume":"76","author":"Abugassa","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib19","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1172\/JCI110570","article-title":"Differential effects of endocrine dysfunction on the axial and the appendicular skeleton","volume":"69","author":"Seeman","year":"1982","journal-title":"J Clin Invest"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.011_bib20","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1210\/jc.2003-030470","article-title":"Effects of an excess and a deficiency of endogenous parathyroid hormone on volumetric bone mineral density and bone geometry determined by peripheral quantitative computed tomography in female subjects","volume":"88","author":"Chen","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib21","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00198-016-3750-0","article-title":"Bone imaging in hypoparathyroidism","volume":"28","author":"Silva","year":"2017","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib22","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J Bone Mineral Res"},{"key":"10.1016\/j.eprac.2025.07.011_bib23","doi-asserted-by":"crossref","DOI":"10.1007\/s00198-025-07410-7","article-title":"Skeletal health status among patients with chronic hypoparathyroidism: results from the Canadian National Hypoparathyroidism Registry (CNHR)","author":"Khan","year":"2025","journal-title":"Osteoporos Int"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.011_bib24","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1002\/jbmr.2273","article-title":"Postsurgical hypoparathyroidism--risk of fractures, psychiatric diseases, cancer, cataract, and infections","volume":"29","author":"Underbjerg","year":"2014","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.011_bib25","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1111\/cen.13895","article-title":"Increased mortality and morbidity in patients with chronic hypoparathyroidism: a population-based study","volume":"90","author":"Vadiveloo","year":"2019","journal-title":"Clin Endocrinol"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib27","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1016\/j.surg.2021.05.004","article-title":"A territory-wide assessment of the incidence of persistent hypoparathyroidism after elective thyroid surgery and its impact on new fracture risk over time","volume":"170","author":"Lui","year":"2021","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib28","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s11914-023-00790-x","article-title":"Fracture risk in patients with hypoparathyroidism","volume":"21","author":"Rejnmark","year":"2023","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232842","article-title":"Prevalence and complications of nonsurgical hypoparathyroidism in Korea: a nationwide cohort study","volume":"15","author":"Kim","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1472-6823-13-1","article-title":"Increased vertebral morphometric fracture in patients with postsurgical hypoparathyroidism despite normal bone mineral density","volume":"13","author":"Mendon\u00e7a","year":"2013","journal-title":"BMC Endocr Disord"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib31","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/clinem\/dgab076","article-title":"Vertebral fracture assessment in postmenopausal women with postsurgical hypoparathyroidism","volume":"106","author":"Cipriani","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.011_bib32","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s40618-022-01818-2","article-title":"Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism","volume":"45","author":"Saha","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib33","doi-asserted-by":"crossref","first-page":"122","DOI":"10.15420\/aer.2019.8.3","article-title":"Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes","volume":"8","author":"El-Sherif","year":"2019","journal-title":"Arrhythm Electrophysiol Rev"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.011_bib34","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1210\/clinem\/dgab162","article-title":"Basal ganglia calcification is associated with local and systemic metabolic mechanisms in adult hypoparathyroidism","volume":"106","author":"Zavatta","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.011_bib35","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1530\/EC-20-0387","article-title":"Prevalence of basal ganglia and carotid artery calcifications in patients with permanent hypoparathyroidism after total thyroidectomy","volume":"9","author":"Lorente-Poch","year":"2020","journal-title":"Endocr Connect"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib36","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1365-2265.2012.04353.x","article-title":"Prevalence and progression of basal ganglia calcification and its pathogenic mechanism in patients with idiopathic hypoparathyroidism","volume":"77","author":"Goswami","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib37","doi-asserted-by":"crossref","first-page":"e2215","DOI":"10.1210\/clinem\/dgab038","article-title":"Impaired immune function in patients with chronic postsurgical hypoparathyroidism: results of the EMPATHY study","volume":"106","author":"Puliani","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib38","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1002\/jbmr.4716","article-title":"Management of hypoparathyroidism","volume":"37","author":"Khan","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib39","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1210\/jc.2015-3910","article-title":"Management of hypoparathyroidism: present and future","volume":"101","author":"Bilezikian","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.011_bib40","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1056\/NEJM198708273170903","article-title":"Gastrointestinal absorption of calcium from milk and calcium salts","volume":"317","author":"Sheikh","year":"1987","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.eprac.2025.07.011_bib41","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1056\/NEJM198904273201703","article-title":"Effect of the time of administration of calcium acetate on phosphorus binding","volume":"320","author":"Schiller","year":"1989","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib42","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.pbiomolbio.2006.02.016","article-title":"Vitamin D physiology","volume":"92","author":"Lips","year":"2006","journal-title":"Prog Biophys Mol Biol"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib43","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and Guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.011_bib44","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s11154-021-09693-7","article-title":"Vitamin D: dosing, levels, form, and route of administration: does one approach fit all?","volume":"22","author":"Bilezikian","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib45","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1210\/endrev\/bnae009","article-title":"Consensus statement on vitamin D status assessment and supplementation: whys, whens, and hows","volume":"45","author":"Giustina","year":"2024","journal-title":"Endocr Rev"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.011_bib46","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1210\/jc.2011-0385","article-title":"Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline","volume":"96","author":"Holick","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.011_bib47","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"173","article-title":"Magnesium homeostasis","author":"Khan","year":"2018"},{"key":"10.1016\/j.eprac.2025.07.011_bib48","series-title":"Magnesium homeostasis. Primer on the metabolic bone diseases and disorders of mineral metabolism","first-page":"173","author":"Khan","year":"2018"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.011_bib49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1056\/NEJM197803162981101","article-title":"Treatment of hypoparathyroid patients with chlorthalidone","volume":"298","author":"Porter","year":"1978","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib50","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12916-022-02419-9","article-title":"Associations of thiazide use with skin cancers: a systematic review and meta-analysis","volume":"20","author":"Shao","year":"2022","journal-title":"BMC Med"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.011_bib51","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1097\/HJH.0000000000002136","article-title":"Reviewing the effects of thiazide and thiazide-like diuretics as photosensitizing drugs on the risk of skin cancer","volume":"37","author":"Kreutz","year":"2019","journal-title":"J Hypertens"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib52","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1172\/JCI100224","article-title":"Studies on the physiology of the parathyroid glands: I. Calcium and phosphorus studies on a case of idiopathic hypoparathyroidism","volume":"7","author":"Albright","year":"1929","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.011_bib53","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.1210\/endo.140.8.6887","article-title":"Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: correlation with osteoclast-like cell formation","volume":"140","author":"Lee","year":"1999","journal-title":"Endocrinology"},{"issue":"12","key":"10.1016\/j.eprac.2025.07.011_bib54","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib55","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1359\/JBMR.0301226","article-title":"PTH differentially regulates expression of RANKL and OPG","volume":"19","author":"Huang","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.07.011_bib56","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"205","article-title":"Parathyroid hormone","author":"Gardella","year":"2018"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib57","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1210\/jc.2017-01555","article-title":"PTH(1\u201334) for surgical hypoparathyroidism: a 2-year prospective, open-label investigation of efficacy and quality of life","volume":"103","author":"Palermo","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.011_bib58","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1210\/jc.2011-1359","article-title":"Long-term results of continuous subcutaneous recombinant PTH (1-34) infusion in children with refractory hypoparathyroidism","volume":"96","author":"Linglart","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.011_bib59","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.jpeds.2014.04.060","article-title":"Effects of pump versus twice-daily injection delivery of synthetic parathyroid hormone 1-34 in children with severe congenital hypoparathyroidism","volume":"165","author":"Winer","year":"2014","journal-title":"J Pediatr"},{"key":"10.1016\/j.eprac.2025.07.011_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bone.2021.115977","article-title":"Therapy with PTH 1-34 or calcitriol and calcium in diverse etiologies of hypoparathyroidism over 27 years at a single tertiary care center","volume":"149","author":"Winer","year":"2021","journal-title":"Bone"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.011_bib61","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1210\/jc.2007-2552","article-title":"Effects of once versus twice-daily parathyroid hormone 1-34 therapy in children with hypoparathyroidism","volume":"93","author":"Winer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib62","first-page":"391","article-title":"Synthetic human parathyroid hormone 1-34 replacement therapy: a randomized crossover trial comparing pump versus injections in the treatment of chronic hypoparathyroidism","volume":"97","author":"Winer","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.011_bib63","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S2213-8587(13)70106-2","article-title":"Efficacy and safety of recombinant human parathyroid hormone (1-84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study","volume":"1","author":"Mannstadt","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.011_bib64","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/jbmr.470","article-title":"The effect of adding PTH(1-84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study","volume":"26","author":"Sikjaer","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.011_bib65","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1210\/jc.2019-00893","article-title":"Therapy of hypoparathyroidism with rhPTH(1-84): a prospective, 8-year investigation of efficacy and safety","volume":"104","author":"Tay","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.011_bib66","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1210\/jc.2018-02430","article-title":"Quality of life in hypoparathyroidism improves with rhPTH(1-84) throughout 8 Years of therapy","volume":"104","author":"Tabacco","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.011_bib67","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eprac.2023.12.001","article-title":"Extended treatment with recombinant human parathyroid hormone (1-84) in adult patients with chronic hypoparathyroidism","volume":"30","author":"Rubin","year":"2024","journal-title":"Endocr Pract"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.011_bib68","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.011_bib69","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3803\/EnM.2024.1916","article-title":"Treatment of hypoparathyroidism by Re-establishing the effects of parathyroid hormone","volume":"39","author":"Rejnmark","year":"2024","journal-title":"Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.011_bib70","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/jbmr.4566","article-title":"Safety and efficacy of PTH 1-34 and 1-84 therapy in chronic hypoparathyroidism: a meta-analysis of prospective trials","volume":"37","author":"Puliani","year":"2022","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.011_bib71","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1002\/jbmr.3824","article-title":"Design and preclinical development of TransCon PTH, an investigational sustained-release PTH replacement therapy for hypoparathyroidism","volume":"34","author":"Holten-Andersen","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib72","doi-asserted-by":"crossref","first-page":"e372","DOI":"10.1210\/clinem\/dgab577","article-title":"PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of TransCon PTH in adult hypoparathyroidism","volume":"107","author":"Khan","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.011_bib73","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1002\/jbmr.4016","article-title":"A randomized double-blind placebo-controlled first-in-human phase 1 trial of TransCon PTH in healthy adults","volume":"35","author":"Karpf","year":"2020","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib74","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/jbmr.4726","article-title":"Efficacy and safety of parathyroid hormone replacement with TransCon PTH in hypoparathyroidism: 26-week results from the phase 3 PaTHway trial","volume":"38","author":"Khan","year":"2023","journal-title":"J Bone Miner Res"},{"issue":"6","key":"10.1016\/j.eprac.2025.07.011_bib75","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1007\/s12325-024-02843-8","article-title":"Palopegteriparatide treatment improves renal function in adults with chronic hypoparathyroidism: 1-year results from the phase 3 PaTHway trial","volume":"41","author":"Rejnmark","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.eprac.2025.07.011_bib76","series-title":"Palopegteriparatide improves skeletal dynamics in adults with chronic hypoparathyroidism: 3-year results from the phase 2 PaTH forward trial presented at: The American society for bone mineral research (ASBMR) 2024","author":"Rubin","year":"2024"},{"key":"10.1016\/j.eprac.2025.07.011_bib77","series-title":"Improved skeletal dynamics in adults treated with palopegteriparatide for hypoparathyroidism: 52-Week analysis of phase 3 PaTHway trial presented at: European calcified Tissue society (ECTS)","author":"Khan","year":"2024"},{"key":"10.1016\/j.eprac.2025.07.011_bib78","series-title":"A single administration of AZP-3601, a novel, long-acting PTH analog, induces a significant and sustained calcemic response: preliminary data from a randomized, double-blind, placebo-controlled phase 1 study","first-page":"A254","volume":"5","author":"Allas","year":"2021"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.011_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/jbm4.10367","article-title":"Optimization of PTH\/PTHrP hybrid peptides to derive a long-acting PTH analog (LA-PTH)","volume":"4","author":"Noda","year":"2020","journal-title":"JBMR Plus"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.011_bib80","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1210\/en.2015-1726","article-title":"Binding selectivity of abaloparatide for PTH-type-1-receptor conformations and effects on downstream signaling","volume":"157","author":"Hattersley","year":"2016","journal-title":"Endocrinology"},{"issue":"7","key":"10.1016\/j.eprac.2025.07.011_bib81","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1002\/jbmr.2811","article-title":"Pharmacodynamic actions of a long-acting PTH analog (LA-PTH) in thyroparathyroidectomized (TPTX) rats and normal monkeys","volume":"31","author":"Shimizu","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.07.011_bib82","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgae121","article-title":"An open-label phase 2 study of eneboparatide, a novel PTH receptor 1 agonist, in hypoparathyroidism","author":"Takacs","year":"2024","journal-title":"The J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.011_bib83","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.4659","article-title":"Autosomal dominant hypocalcemia type 1: a systematic review","volume":"37","author":"Roszko","year":"2022","journal-title":"J Bone Mineral Res"},{"issue":"5","key":"10.1016\/j.eprac.2025.07.011_bib84","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1093\/hmg\/5.5.601","article-title":"Mutations in the Ca(2+)-sensing receptor gene cause autosomal dominant and sporadic hypoparathyroidism","volume":"5","author":"Baron","year":"1996","journal-title":"Hum Mol Genet"},{"issue":"15","key":"10.1016\/j.eprac.2025.07.011_bib85","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1056\/NEJM199610103351505","article-title":"A familial syndrome of hypocalcemia with hypercalciuria due to mutations in the calcium-sensing receptor","volume":"335","author":"Pearce","year":"1996","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.eprac.2025.07.011_bib86","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1111\/bph.14086","article-title":"Calcimimetic and calcilytic therapies for inherited disorders of the calcium-sensing receptor signalling pathway","volume":"175","author":"Hannan","year":"2018","journal-title":"Br J Pharmacol"},{"issue":"9","key":"10.1016\/j.eprac.2025.07.011_bib87","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1002\/jbmr.3747","article-title":"Treatment of autosomal dominant hypocalcemia type 1 with the calcilytic NPSP795 (SHP635)","volume":"34","author":"Roberts","year":"2019","journal-title":"J Bone Miner Res"},{"issue":"13","key":"10.1016\/j.eprac.2025.07.011_bib88","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1056\/NEJMc2302708","article-title":"Efficacy and safety of encaleret in autosomal dominant hypocalcemia type 1","volume":"389","author":"Gafni","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2025.07.011_bib89","article-title":"MBX 2109, a once-weekly parathyroid hormone replacement therapy prodrug: phase 1, first-in-human, randomized trial","author":"Carney","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"Supplement_1","key":"10.1016\/j.eprac.2025.07.011_bib90","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvae163.386","article-title":"9263 characterization of A novel oral small molecule PTH1R agonist: proof of concept for an alternative to injectable peptide-based therapy for hypoparathyroidism","volume":"8","author":"Zhang","year":"2024","journal-title":"J Endocr Soc"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.011_bib91","first-page":"3480","article-title":"A randomized, cross-over trial of once-daily versus twice-daily parathyroid hormone 1-34 in treatment of hypoparathyroidism","volume":"83","author":"Winer","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.011_bib92","article-title":"Palopegteriparatide improves skeletal dynamics in adults with chronic hypoparathyroidism: 162-week results from the phase 2 PaTH forward trial","author":"Tsourdi","year":"2025","journal-title":"Osteologie"},{"issue":"4","key":"10.1016\/j.eprac.2025.07.011_bib93","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1210\/clinem\/dgae693","article-title":"Efficacy and safety of TransCon PTH in adults with hypoparathyroidism: 52-week results from the phase 3 PaTHway trial","volume":"110","author":"Clarke","year":"2024","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009693?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X25009693?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:51:39Z","timestamp":1772743899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X25009693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":93,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1530891X25009693"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.011","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Hypoparathyroidism\u2014Current and Emerging Therapies","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of the AACE.","name":"copyright","label":"Copyright"}]}}